文献速递淋巴瘤

利妥昔单抗、氟达拉滨、米托蒽醌和地塞米松(R-FND)联合干扰素维持治疗惰性淋巴瘤的十年缓解率高:一项随机研究结果

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
PubMed 文献 · Br J Haematol · 2017-03-24

这项单中心随机研究纳入158例晚期初治惰性淋巴瘤患者,比较FND同步或序贯联合利妥昔单抗后干扰素维持治疗的疗效与安全性。完全缓解/未经证实的完全缓解率分别为89%和93%,12.5年随访时两组无显著差异,10年总生存率分别为76%和73%,10年无进展生存率分别为52%和51%。

要点

  • 完全缓解/未经证实的完全缓解率分别为89%和93%。
  • 12.5年随访时,两组基于治疗方案的各项结局均无显著差异。
  • 10年总生存率分别为76%和73%,10年无进展生存率分别为52%和51%。

核心结论

  • FND同步或序贯联合利妥昔单抗及干扰素维持治疗惰性淋巴瘤显示出高缓解率和稳健的生存。

研究设计与样本

  • 单中心随机研究,纳入1997年至2002年间入组的158例晚期初治惰性淋巴瘤患者。
  • 患者随机接受6-8周期FND后6个月利妥昔单抗月度剂量,或6剂利妥昔单抗与FND同步给予。
  • 所有至少达到部分缓解的患者接受12个月干扰素维持治疗。

主要发现

  • 两组中位年龄分别为54岁和55岁。
  • FND后利妥昔单抗组女性比例较高(65% vs 43%),基线贫血比例较高(23% vs 11%)。
  • 完全缓解/未经证实的完全缓解率分别为89%和93%。
  • 最常见的≥3级毒性为中性粒细胞减少(86% vs 96%),中性粒细胞减少性发热发生率分别为21%和16%。
  • 晚期毒性包括骨髓增生异常综合征(n=3)和急性髓系白血病(n=5)。

关键数值与推荐

  • 10年总生存率估计分别为76%和73%。
  • 10年无进展生存率估计分别为52%和51%。
  • 12.5年随访时,基于治疗方案的各项结局均无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report a single-centre, randomized study evaluating the efficacy and safety of concurrent fludarabine, mitoxantrone, dexamethasone (FND) and rituximab versus sequential FND followed by rituximab in 158 patients with advanced stage, previously untreated indolent lymphoma, enrolled between 1997 and 2002. Patients were randomized to 6-8 cycles of FND followed by 6 monthly doses of rituximab or 6 doses of rituximab given concurrently with FND. All patients who achieved at least a partial response received 12 months of interferon (IFN) maintenance. Median ages were 54 and 55 years. The two groups were comparable with the exception of a higher percentage of females (65% vs. 43%) and baseline anaemia (23% vs. 11%) in the FND followed by rituximab group. Complete response/unconfirmed complete response rates were 89% and 93%. The most frequent grade ≥ 3 toxicity was neutropenia (86% vs. 96%). Neutropenic fever occurred in 21% and 16%. Late toxicity included myelodysplastic syndrome (n = 3) and acute myeloid leukaemia (n = 5). With 12·5 years of follow-up, no significant differences based on treatment schedule were observed. 10-year overall survival estimates were 76% and 73%. 10-year progression-free survival estimates were 52% and 51%. FND with concurrent or sequential rituximab, and IFN maintenance in indolent lymphoma demonstrated high response rates and robust survival.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Nastoupil LJ, McLaughlin P, Feng L, et al. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol. 2017. PMID: 28340281. doi:10.1111/bjh.14541

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。